Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIA Adaptive Randomized Trial of Dalotuzumab Plus Irinotecan Versus Cetuximab Plus Irinotecan in Metastatic Rectal Cancer
2012-000317-36Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dalotuzumab in rectal cancer (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Apr 2012; status: completed.
02
Drugs
dalotuzumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2012-000317-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000317-36.